These results supported the FDA approval of inavolisib plus palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor–positive, HER2-negative, advanced or metastatic breast cancer in October 2024.

Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb Visitweb